Ira Duarte's most recent trade in Heron Therapeutics Inc was a trade of 3,874 Restricted Stock Units done . Disclosure was reported to the exchange on July 19, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2026 | 3,874 | 23,246 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2026 | 3,874 | 264,947 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 19 Jul 2026 | 1,101 | 263,846 (0%) | 0% | 0.5 | 517 | Common Stock |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2026 | 12,500 | 264,628 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2026 | 12,500 | 12,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.38 per share. | 16 Jun 2026 | 3,555 | 261,073 (0%) | 0% | 0.4 | 1,351 | Common Stock |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 13,535 | 203,027 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 13,535 | 252,128 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 11,694 | 227,570 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2026 | 11,694 | 128,638 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2026 | 3,874 | 215,876 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2026 | 3,874 | 27,120 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 11,695 | 195,356 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 11,695 | 140,332 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 216,562 | 216,562 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2026 | 216,561 | 216,561 | - | - | Performance Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2026 | 3,875 | 183,661 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2026 | 3,875 | 30,994 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 11,694 | 152,027 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2025 | 11,694 | 179,786 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2025 | 3,874 | 34,869 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2025 | 3,874 | 168,092 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2025 | 11,695 | 163,721 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2025 | 11,695 | 164,218 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2025 | 3,874 | 38,743 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2025 | 3,874 | 152,523 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 12,500 | 25,000 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 12,500 | 148,649 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Duarte Ira | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 11,694 | 175,416 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 11,694 | 136,149 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2025 | 3,875 | 42,617 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2025 | 3,875 | 124,455 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 374,220 | 374,220 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 187,110 | 187,110 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 120,580 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2025 | 3,874 | 46,492 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 50,366 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2024 | 3,874 | 108,001 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 104,127 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2024 | 3,875 | 54,240 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,500 | 100,252 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 12,500 | 37,500 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 88,874 (0%) | 0% | - | Common Stock | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2024 | 3,874 | 58,115 | - | - | Restricted Stock Units | |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.64 per share. | 19 Apr 2024 | 1,122 | 87,752 (0%) | 0% | 2.6 | 2,962 | Common Stock |
| Heron Therapeutics Inc | Ira Duarte | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 371,935 | 371,935 | - | - | Employee Stock Option (Right to Buy) | |
| Heron Therapeutics Inc | Duarte Ira | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 61,989 | 61,989 | - | - | Restricted Stock Units |